Tegafur,Gimeracil and Oteracil Potassium

Generic Name
Tegafur,Gimeracil and Oteracil Potassium
Brand Names
-
Drug Type
-
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Indication

用于不能切除的局部晚期或转移性胃癌。

用于治疗成人胆道癌【日本PMDA已批准；《胆管癌诊断与治疗-外科专家共识》】。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

First Posted Date
2018-02-28
Last Posted Date
2020-03-06
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
1191
Registration Number
NCT03448549
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, Beijing, China

SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

First Posted Date
2018-02-23
Last Posted Date
2019-08-22
Lead Sponsor
National Health Research Institutes, Taiwan
Target Recruit Count
130
Registration Number
NCT03443492
Locations
🇨🇳

National Institute of Cancer Research, Miaoli, Taiwan

Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer

First Posted Date
2017-12-21
Last Posted Date
2021-03-08
Lead Sponsor
Fujian Cancer Hospital
Registration Number
NCT03380689
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer

First Posted Date
2017-08-02
Last Posted Date
2017-08-02
Lead Sponsor
Harbin Medical University
Target Recruit Count
110
Registration Number
NCT03237507
Locations
🇨🇳

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

First Posted Date
2017-05-22
Last Posted Date
2022-04-07
Lead Sponsor
National Health Research Institutes, Taiwan
Target Recruit Count
18
Registration Number
NCT03162510
Locations
🇨🇳

Taiwan Cooperative Oncology Group, National Health Research Institutes, Taipei, Taiwan

Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer

First Posted Date
2017-05-02
Last Posted Date
2017-05-08
Lead Sponsor
Fujian Cancer Hospital
Target Recruit Count
47
Registration Number
NCT03137004
Locations
🇨🇳

Rongbo Lin, Fuzhou, Fujian, China

The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer

First Posted Date
2017-01-02
Last Posted Date
2017-09-27
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
20
Registration Number
NCT03007446
Locations
🇨🇳

the chinese PLA General Hospital, Beijing, China

Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01

First Posted Date
2016-12-02
Last Posted Date
2020-07-21
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
350
Registration Number
NCT02979691
Locations
🇨🇳

Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.

Phase 2
Conditions
Nasopharyngeal Carcinoma
Interventions
Drug: S-1
First Posted Date
2016-08-25
Last Posted Date
2017-01-11
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
53
Registration Number
NCT02878889
Locations
🇨🇳

Xiaozhong Chen, Hangzhou, Zhejiang, China

🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2016-08-11
Last Posted Date
2020-12-24
Lead Sponsor
Gilead Sciences
Target Recruit Count
36
Registration Number
NCT02862535
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy